Rein Therapeutics Inc.
NASDAQ: RNTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- James Brian Windsor
- Employees
- 11
- Headquarters
- Austin, United States
- IPO year
- 2017
- Market cap
- $28.2M
- Website
- http://www.reintx.com
Loading RNTX…
Loading profile data…Frequently asked questions about RNTX
What does Rein Therapeutics Inc. (RNTX) do?
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction be...
Where does RNTX trade?
Rein Therapeutics Inc. (RNTX) trades on the NASDAQ Global Market.
What sector is RNTX in?
Rein Therapeutics Inc. (RNTX) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Rein Therapeutics Inc.?
James Brian Windsor is the chief executive officer of Rein Therapeutics Inc. (RNTX).
Where is Rein Therapeutics Inc. headquartered?
Rein Therapeutics Inc. is headquartered in United States.
Does RNTX pay a dividend?
Rein Therapeutics Inc. (RNTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNTX go public?
Rein Therapeutics Inc. (RNTX) completed its initial public offering in 2017.